<DOC>
	<DOCNO>NCT01267734</DOCNO>
	<brief_summary>Objectives 1 . To compare safety long-term effectiveness coronary stenting new platform Everolimus-Eluting coronary stenting system ( EECSS , Promus Element ) compare Zotarolimus-Eluting coronary stenting system ( ZECSS , Endeavor Resolute ) patient coronary heart disease ( CHD ) 2 . To determine short-term efficacy safety triple anti-platelet therapy ( TAT , Aspirin 100mg qd , Clopidogrel 75mg qd Cilostazol 100mg bid ) compare double-dose clopidogrel dual anti-platelet therapy ( DDAT , Aspirin 100mg qd Clopidogrel 150mg qd ) patient undergo percutaneous coronary intervention ( PCI ) drug-eluting stent ( DES ) Study design Prospective , open-label , 2-by-2 multifactorial , randomize , multicenter trial test follow CHD patient 1 . Non-inferiority Promus Element stent compare Endeavor Resolute stent reduce target lesion failure ( TLF ) 2 . Non-inferiority TAT compare DDAT reduce net clinical outcome Patients randomize 2-by-2 factorial manner accord type drug elute stent ( EECSS vs. ZECSS ) type anti-platelet regimen ( TAT vs. DDAT ) . Randomization also stratify per presence DM . Patient enrollment 3750 patient enrol 50 center Republic Korea Patient follow-up Clinical follow-up occur 1 , 3 , 12 , 24 , 36 month procedure . Angiographical follow-up recommend participant 13 month procedure . Investigator designee may conduct follow-up telephone contact office visit . Primary endpoint 1 . Target lesion failure ( TLF ) , define composite cardiac death , target vessel-related myocardial infarction ( MI ) ischemia-driven target lesion revascularization ( TLR ) 12 month stent arm 2 . Net clinical outcome , define composite cardiac death , nonfatal MI , CVA major bleed PLATO criterion 1 month anti-platelet arm</brief_summary>
	<brief_title>Harmonizing Optimal Strategy Treatment Coronary Artery Stenosis - SAfety &amp; EffectiveneSS Drug-ElUting Stents &amp; Anti-platelet REgimen</brief_title>
	<detailed_description>Secondary endpoint 1 . Clinical laboratory endpoint 1 month All death cardiac death Myocardial infarction ( q wave non-q wave ) Stent thrombosis ( definite possible ) CVA ( hemorrhagic non-hemorrhagic ) Bleeding ( major minor ) VerifyNow ASA VerifyNow P2Y12 2 . Clinical endpoint 12 month All death cardiac death Target vessel-related MI MI ( q wave non-q wave ) Target vessel/lesion revascularization ( ischemia-driven ) Stent thrombosis ( definite/possible/probable ) Net clinical outcome include bleeding ( major minor ) Acute success procedure ( device , lesion procedure ) 3 . Angiographic ( include IVUS OCT ) endpoint 13 month In-stent &amp; In-segment late loss In-stent &amp; In-segment % diameter stenosis Angiographic pattern restenosis Neointimal volume , % neointimal volume % volume obstruction IVUS OCT Degree stent strut endothelialization OCT</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>General Inclusion Criteria Subject must least 18 year age . Subject able verbally confirm understandings risk , benefit treatment alternative receive Promus Element Endeavor Resolute stent , he/she his/her legally authorize representative provide write informed consent prior study related procedure . Subject must significant lesion ( &gt; 50 % visual estimate ) coronary artery , venous arterial bypass graft . Subject must evidence myocardial ischemia ( e.g. , stable , unstable angina , recent infarction , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia ) . In subject diameter stenosis &gt; 70 % , evidence myocardial ischemia document . Angiographic Inclusion Criteria Target lesion ( ) must locate coronary artery , venous arterial bypass graft diameter ≥ 2.5 mm ≤ 4.00 mm . Target lesion ( ) must amenable percutaneous coronary intervention . Exclusion criteria The patient know hypersensitivity contraindication follow medication : Heparin , Aspirin , Clopidogrel , Cilostazol , Everolimus , Zotarolimus , Contrast medium ( Patients document sensitivity contrast medium effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Those true anaphylaxis prior contrast medium , however , enrol . ) Systemic ( intravenous ) Everolimus Zotarolimus use within 12 month . Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study . History bleed diathesis , know coagulopathy ( include heparininduced thrombocytopenia ) , abnormal hemogram ( Hb &lt; 10g/dL PLT count &lt; 100,000/μL ) refuse blood transfusion Patients severe LV systolic dysfunction ( LVEF &lt; 25 % ) cardiogenic shock Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . Patients actively participate another drug device investigational study , complete primary endpoint followup period . Symptomatic heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Everolimus</keyword>
	<keyword>Zotarolimus</keyword>
	<keyword>Cilostazol</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>